FT516-102:A Phase I, Open-Label, Multicenter Study of FT516 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors
|Effective start/end date||2/20/20 → 3/1/23|
- FATE THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.